Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib + SRS/SRT in EGFR-Mutant NSCLC with Brain Metastases
NCT07911449Phase 2Recruiting
- Sponsor
- Cho Ray Hospital
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), brain metastases, sponsored by Cho Ray Hospital. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT07911449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911449.